Finance

Beta
Lists
GPCR:NASDAQ
Structure Therapeutics Inc
$55.14
+0.46%
(+0.25) 1D
$55.45
+0.56% (+0.31)
After hours
Closed: Jul 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GPCR...
Open
$54.08
High
$55.48
Low
$54.00
Mkt. cap
4.04B
Avg. vol.
838.82K
Volume
459.67K
52-wk high
$94.90
52-wk low
$15.80
EPS
-$2.72
Beta
-1.58
Shares outstanding
71.07M
No. of employees
233
Open
$54.08
High
$55.48
Low
$54.00
Mkt. cap
4.04B
Avg. vol.
838.82K
Volume
459.67K
52-wk high
$94.90
52-wk low
$15.80
EPS
-$2.72
Beta
-1.58
Shares outstanding
71.07M
No. of employees
233
News stories
From sources across the web
About Structure Therapeutics Inc
CEO-
Employees233
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websitestructuretx.com
Analyst ratings
Based on 8 analysts giving stock ratings to GPCR in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GPCR in the last 3 months.
Highest
Current $55.14
$145.00 (+162.97%)
Average
$110.17 (+99.80%)
Lowest
$70.00 (+26.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$70.00
+26.9%
06/11/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
-
-
06/09/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
$101.00
+83.2%
06/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
06/08/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$145.00
+163%
06/05/2026
Patrick Dolezal
LifeSci Capital
Buy
Reiterated
$104.00
+88.6%
05/09/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$101.00
+83.2%
05/08/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$140.00
+153.9%
05/07/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$101.00
+83.2%
03/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
$100.00
+81.4%
03/16/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$90.00
+63.2%
02/27/2026
Roger Song
Jefferies
Buy
Maintained
$125.00
+126.7%
02/27/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$126.00
+128.5%
02/27/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+68.7%
02/27/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$113.00
+104.9%
02/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
54.71M
58.99M
68.69M
66.51M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.74M
14.80M
17.57M
22.87M
Operating expense
70.45M
73.79M
-13.74M
89.38M
Total operating expenses
70.45M
73.79M
-13.74M
89.38M
Operating income
-70.45M
-73.79M
13.74M
-89.38M
Other non operating income
-
-
-13.86M
-
EBT including unusual items
-61.52M
-65.60M
33.17M
-75.78M
EBT excluding unusual items
-61.52M
-65.60M
35.75M
-75.78M
Income tax expense
139.00K
108.00K
170.00K
190.00K
Effective tax rate
-0.23%
-0.16%
0.51%
-0.25%
Other operating expenses
-
-
-100.00M
-
Net income
-61.66M
-65.71M
33.00M
-75.97M
Net profit margin
-
-
-
-
Earnings per share
-0.36
-0.37
-0.46
-0.35
Interest and investment income
8.93M
8.18M
35.87M
13.60M
Interest expense
-
-
-
-
Net interest expenses
8.93M
8.18M
35.87M
13.60M
Depreciation and amortization charges
-
-
-
-
EBITDA
-70.16M
-73.41M
14.47M
-88.79M
Gain or loss from assets sale
-
-
-10.25M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer